• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Acute Promyelocytic Leukemia - Pipeline Review, H2 2012 Product Image

Acute Promyelocytic Leukemia - Pipeline Review, H2 2012

  • ID: 2366367
  • December 2012
  • 74 pages
  • Global Markets Direct

Acute Promyelocytic Leukemia – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Acute Promyelocytic Leukemia - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Acute Promyelocytic Leukemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acute Promyelocytic Leukemia. Acute Promyelocytic Leukemia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Acute Promyelocytic Leukemia.
- A review of the Acute Promyelocytic READ MORE >

2
List of Tables 5
List of Figures 5
Introduction 6
REPORT COVERAGE 6
Acute Promyelocytic Leukemia Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Acute Promyelocytic Leukemia 8
Acute Promyelocytic Leukemia Therapeutics under Development by Companies 10
Acute Promyelocytic Leukemia Therapeutics under Investigation by Universities/Institutes 11
Late Stage Products 13
Comparative Analysis 13
Mid Clinical Stage Products 14
Comparative Analysis 14
Early Clinical Stage Products 15
Comparative Analysis 15
Pre-Clinical Stage Products 16
Comparative Analysis 16
Acute Promyelocytic Leukemia Therapeutics – Products under Development by Companies 17
Acute Promyelocytic Leukemia Therapeutics – Products under Investigation by Universities/Institutes 18
Companies Involved in Acute Promyelocytic Leukemia Therapeutics Development 20
Telik, Inc. 20
Array BioPharma Inc. 21
TMRC Co., Ltd. 22
Acute Promyelocytic Leukemia – Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Combination Products 24
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
ARRY-520 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
TLK-58747 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
tamibarotene - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
tamibarotene - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Clofarabine + Cyclophosphamide - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Tretinoin + Cytarabine + Daunorubicin + Arsenic Trioxide + Gemtuzumab + Methotrexate + Mercaptopurine - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 39
Tretinoin + Arsenic Trioxide + Idarubicin - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Tretinoin + Gemtuzumab Ozogamicin + Arsenic trioxide + Daunorubicin + Mercaptopurine + Methotrexate - Drug Profile 41
Product Description 41
Mechanism of Action 42
R&D Progress 42
Tretinoin + Cytarabine + Daunorubicin + Mercaptopurine + Methotrexate - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Tretinoin + Cytarabine + Daunorubicin + Mercaptopurine + Methotrexate + Arsenic Trioxide - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 47
Trisenox + Cytarabine + Idarubicin + Mercaptopurine + Methotrexate + Mitoxantrone Hydrochloride + Tretinoin - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 49
All-Trans Retinoic Acid + Arsenic Trioxide + Idarubicin + Methylprednisolone - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Arsenic Trioxide + Cytarabine + Daunorubicin + Mercaptopurine + Methotrexate + Tretinoin - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 52
All-Trans Retinoic Acid + Arsenic Trioxide + Idarubicin - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Filgrastim + Lintuzumab + Arsenic Trioxide + Idarubicin + Tretinoin - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
p.DOM-WT1-37 DNA Vaccine + p.DOM-WT1-126 DNA Vaccine - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
All-Trans Retinoic Acid + Arsenic Trioxide + Gemtuzumab Ozogamicin + Methylprednisolone - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Arsenic Trioxide - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Arsenic Trioxide + Gemtuzumab - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Arsenic Trioxide + All Transretinoic Acid - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Acute Promyelocytic Leukemia Therapeutics – Drug Profile Updates 63
Acute Promyelocytic Leukemia Therapeutics – Discontinued Products 67
Acute Promyelocytic Leukemia Therapeutics - Dormant Products 68
Acute Promyelocytic Leukemia – Product Development Milestones 70
Featured News & Press Releases 70
Jul 09, 2012: CytRx Announces Allowance Of US Patent Application For Tamibarotene Capsule 70
Apr 18, 2011: CytRx Announces Publication Of Peer-Reviewed Case Report Documenting Tamibarotene's Successful Elimination Of Recurrent Advanced-Stage Leukemia 70
Dec 07, 2009: CytRx Announces Positive Phase II Results Of Tamibarotene For The Treatment Of Relapsed Acute Promyelocytic Leukemia 71
Appendix 73
Methodology 73
Coverage 73
Secondary Research 73
Primary Research 73
Expert Panel Validation 73
Contact Us 74
Disclaimer 74

List of Tables
Number of Products Under Development for Acute Promyelocytic Leukemia, H2 2012 8
Products under Development for Acute Promyelocytic Leukemia – Comparative Analysis, H2 2012 9
Number of Products under Development by Companies, H2 2012 10
Number of Products under Investigation by Universities/Institutes, H2 2012 12
Comparative Analysis by Late Stage Development, H2 2012 13
Comparative Analysis by Mid Clinical Stage Development, H2 2012 14
Comparative Analysis by Early Clinical Stage Development, H2 2012 15
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 16
Products under Development by Companies, H2 2012 17
Products under Investigation by Universities/Institutes, H2 2012 18
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 19
Telik, Inc., H2 2012 20
Array BioPharma Inc., H2 2012 21
TMRC Co., Ltd., H2 2012 22
Assessment by Monotherapy Products, H2 2012 23
Assessment by Combination Products, H2 2012 24
Assessment by Stage and Route of Administration, H2 2012 26
Assessment by Stage and Molecule Type, H2 2012 28
Acute Promyelocytic Leukemia Therapeutics – Drug Profile Updates 63
Acute Promyelocytic Leukemia Therapeutics – Discontinued Products 67
Acute Promyelocytic Leukemia Therapeutics – Dormant Products 68
Acute Promyelocytic Leukemia Therapeutics – Dormant Products (Contd..1) 69

List of Figures
Number of Products under Development for Acute Promyelocytic Leukemia, H2 2012 8
Products under Development for Acute Promyelocytic Leukemia – Comparative Analysis, H2 2012 9
Products under Development by Companies, H2 2012 10
Products under Investigation by Universities/Institutes, H2 2012 11
Late Stage Products, H2 2012 13
Mid Clinical Stage Products, H2 2012 14
Early Clinical Stage Products, H2 2012 15
Pre-Clinical Stage Products, H2 2012 16
Assessment by Monotherapy Products, H2 2012 23
Assessment by Combination Products, H2 2012 24
Assessment by Route of Administration, H2 2012 25
Assessment by Stage and Route of Administration, H2 2012 26
Assessment by Molecule Type, H2 2012 27
Assessment by Stage and Molecule Type, H2 2012 28

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos